• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Compass Therapeutics Inc.

    4/29/26 8:09:34 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CMPX alert in real time by email
    DEFA14A 1 edge20068103x2_defa14a.htm DEFA14A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934

    Filed by the Registrant ☒
    Filed by a party other than the Registrant  ☐

    Check the appropriate box:
    ☐
    Preliminary Proxy Statement
    ☐
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐
    Definitive Proxy Statement
    ☒
    Definitive Additional Materials
    ☐
    Soliciting Material Pursuant to §240.14a-12

    Compass Therapeutics, Inc.
    (Name of Registrant as Specified In Its Charter)
     
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):
    ☒
    No fee required.
    ☐
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
    ☐
    Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.





    Get the next $CMPX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CMPX

    DatePrice TargetRatingAnalyst
    4/28/2026Outperform → Mkt Perform
    Raymond James
    2/13/2026$15.00Buy
    Craig Hallum
    1/5/2026Outperform
    William Blair
    12/3/2025$10.00Mkt Outperform
    Citizens JMP
    12/3/2025$10.00Buy
    Canaccord Genuity
    12/3/2025Overweight
    Cantor Fitzgerald
    7/1/2025$9.00Outperform
    Raymond James
    4/2/2025$6.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $CMPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Accounting Officer Lerner Neil bought $28,350 worth of shares (15,000 units at $1.89), increasing direct ownership by 4% to 397,500 units (SEC Form 4)

    4/A - Compass Therapeutics, Inc. (0001738021) (Issuer)

    4/30/26 4:00:48 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: General Counsel Anderman Jonathan bought $47,250 worth of shares (25,000 units at $1.89), increasing direct ownership by 15% to 196,000 units (SEC Form 4)

    4/A - Compass Therapeutics, Inc. (0001738021) (Issuer)

    4/30/26 4:00:25 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    General Counsel Anderman Jonathan was granted 25,000 shares, increasing direct ownership by 15% to 196,000 units (SEC Form 4)

    4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

    4/29/26 5:11:59 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Compass Therapeutics to Participate in Upcoming June Investor Events

    BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of June. Details are as follows: Jefferies Global Healthcare ConferenceDate: Thursday, June 4, 2026 Time: 8:45 AM ETWebcast Link: https://cmpx.info/jefferies Goldman Sachs 47th Annual Global Healthcare ConferenceDate: Tuesday, June 9, 2026 Time: 8:00 AM ETWebcast Link: https://cmpx.info/gs Virtual/Replay availability: Presentations will be archived on Compass' Ev

    5/28/26 7:30:00 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting

    CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with advanced malignancies resistant to prior immune checkpoint inhibitors.Deep and durable responses were observed in patients with triple-negative breast cancer (TNBC), Hodgkin lymphoma (HL), and non-small cell lung cancer (NSCLC).CTX-8371 was generally well tolerated with no observed dose limiting toxicities (DLTs). BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based th

    5/21/26 5:00:00 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics to Participate in Upcoming May Investor Events

    BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of May. Details are as follows: H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ Date: Tuesday, May 19, 2026 Time: 1:30 PM ETWebcast Link: https://journey.ct.events/view/bc55d2f9-d121-4f7d-8129-1f69f201bd7f 2026 Stifel Virtual Targeted Oncology ForumDate: Wednesday, May 20, 2026 Time: 11:30 AM ETWebcast Link: https://event.summitcast.com/view/SS

    5/12/26 7:30:00 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Accounting Officer Lerner Neil bought $28,350 worth of shares (15,000 units at $1.89), increasing direct ownership by 4% to 397,500 units (SEC Form 4)

    4/A - Compass Therapeutics, Inc. (0001738021) (Issuer)

    4/30/26 4:00:48 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: General Counsel Anderman Jonathan bought $47,250 worth of shares (25,000 units at $1.89), increasing direct ownership by 15% to 196,000 units (SEC Form 4)

    4/A - Compass Therapeutics, Inc. (0001738021) (Issuer)

    4/30/26 4:00:25 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF EXECUTIVE OFFICER Schuetz Thomas J. bought $21,100 worth of shares (10,000 units at $2.11), increasing direct ownership by 0.15% to 6,480,825 units (SEC Form 4)

    4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

    5/27/25 3:24:21 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Compass Therapeutics Inc.

    SCHEDULE 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)

    5/15/26 4:06:36 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Compass Therapeutics Inc.

    10-Q - Compass Therapeutics, Inc. (0001738021) (Filer)

    5/5/26 8:01:07 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Compass Therapeutics, Inc. (0001738021) (Filer)

    5/5/26 7:30:18 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Compass Therapeutics downgraded by Raymond James

    Raymond James downgraded Compass Therapeutics from Outperform to Mkt Perform

    4/28/26 7:42:31 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Craig Hallum initiated coverage on Compass Therapeutics with a new price target

    Craig Hallum initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $15.00

    2/13/26 8:35:30 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    William Blair initiated coverage on Compass Therapeutics

    William Blair initiated coverage of Compass Therapeutics with a rating of Outperform

    1/5/26 8:57:39 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    Financials

    Live finance-specific insights

    View All

    Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer

    Webcast scheduled for Monday, April 27, 2026 at 8:00am ET. BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Monday, April 27, 2026 at 8:00am ET to review topline secondary endpoints from its Phase 2/3 COMPANION-002 clinical study assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC).  Conference Call and Webcast Presentation: Date and Time: Monday, April 27, 2026 at 8:00am ET Toll Fre

    4/24/26 4:00:00 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

    In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe this may suggest that tovecimig could be affecting overall survival in the patient population. As a result, the analysis of the secondary endpoints, including overall survival, is now expected in Q1 2026.In the ongoing Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody) in patients treated in the post-checkpoint inhibitor setting, two deep and confirmed partial responses have been observed to date. A patient with non-small cell lung cancer had a 100% reduction in target le

    8/11/25 7:00:00 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

    BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, will release its financial results for the quarter ended June 30, 2025 and host a webcast and conference call to provide an update on the ongoing tovecimig Phase 2/3 study, clinical data for CTX-8371 and preclinical data for CTX-10726, on Monday, August 11, 2025, at 8:00 a.m. ET. Call Details: Date: Monday, August 11, 2025 Time: 8:00 AM ET Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1727543&tp_key=955a2c2f4d Dial-In: 1-877-407-9716 (US), 1-201-493-6779 (International), 13754954 (Co

    8/8/25 4:01:00 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    Leadership Updates

    Live Leadership Updates

    View All

    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

    VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),

    1/14/26 10:39:59 AM ET
    $BNTX
    $CMPX
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Compass Therapeutics Announces Key Leadership Appointments

    BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointments of Arjun Prasad, MBA, MPH as Chief Commercial Officer and Cynthia Sirard, MD as Chief Medical Officer, both effective as of January 1, 2026. "We are thrilled to welcome Arjun and Cyndi to the Compass team. They are highly accomplished leaders with decades of commercial and clinical development experience," said Thomas Schuetz, MD, PhD, CEO of Compass and Vice Chairman of the Board of Directors. "Arjun's world-class expertise in on

    1/5/26 8:00:00 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

    BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointment of Barry Shin as Chief Financial Officer, as of December 9, 2024. Mr. Shin is a veteran biopharmaceutical leader with over 20 years of experience as a finance and operations executive, investment banker, and corporate advisor. "We are delighted to welcome Barry to Compass during this pivotal and exciting time for the company," said Thomas Schuetz, MD, PhD, CEO of Compass and Vice Chairman of the Board of Directors. "We have severa

    12/10/24 8:00:00 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Compass Therapeutics Inc.

    SC 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)

    11/14/24 10:00:35 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Compass Therapeutics Inc.

    SC 13G - Compass Therapeutics, Inc. (0001738021) (Subject)

    8/2/24 4:15:57 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Compass Therapeutics Inc. (Amendment)

    SC 13D/A - Compass Therapeutics, Inc. (0001738021) (Subject)

    3/22/24 4:59:51 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care